Targeted Markets MBF Therapeutics specializes in animal health immunotherapeutics with a focus on respiratory viral diseases such as PRRS and ASF, presenting sales opportunities with swine producers, veterinary distributors, and regulatory bodies seeking safer, effective DNA-based vaccines.

Platform Differentiation The T-Max DNA vaccine platform offers cross-protective antigen design, non-antibiotic plasmid selection, and immunomodulators, enabling solutions that may outperform traditional KWV/MLV vaccines and appeal to customers requiring safer, durable vaccines for herds.

Strategic Partnerships Historical collaborations with MRIGlobal and high-profile board appointments indicate a readiness to engage with research partners and pharma-like collaborations, signaling BD opportunities for co-development, licensing, or joint ventures.

Rapid Growth Signals Revenue is in the low-to-mid single digits with ongoing fundraising, suggesting a time window for early adopters and strategic investors to gain access to pipeline vaccines and first-mover advantages in ASFV and PRRS programs.

Global Risk Context ASF and PRRS present global economic and trade disruption pressures, creating a compelling case for animal health vaccine procurement, biosecurity solutions, and regional distribution deals to mitigate risk for large pork production networks.